NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The Global Acute Ischemic Stroke Therapeutics Market size is estimated to grow by USD 1.74 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 6.1% during the forecast period.Rising prevalence of cardiovascular diseases is driving market growth, with a trend towards integrating genomic and clinical data through translational bioinformatics in acute ischemic stroke management.
However, unmet needs for anticoagulant reversal agents poses a challenge - Key market players include Amgen Inc., AstraZeneca Plc, Athersys Inc., Bayer AG, Biogen Inc.
, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd.
, F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc.
, Medtronic PLC, Merck and Co. Inc., NoNO Inc.
, Pfizer Inc., SanBio Co. Ltd.
, Sanofi SA, Stryker Corp., and Teva Pharmaceutical Industries Ltd..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver Acute Ischemic Stroke (AIS) is a complex cardiac disorder requiring integration of genotypic and clinical data for effective treatment and prevention. Modern approaches, such as Translational Bioinformatics (TBI), are being developed to analyze heterogeneous features from bioinformatics, biostatistics, statistical genetics , and clinical informatics.
TBI acts as a dat.